Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.

GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Ocrelizumab may cause pancreatitis in some patients.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Rituximab may cause skin issues, but baricitinib can help improve them.

GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.

A woman got unwanted hair growth on her face from using bimatoprost eyedrops for glaucoma.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Deucravacitinib may effectively treat discoid lupus erythematosus.

Upadacitinib improved multiple immune-related conditions in one patient.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.